Biocryst Pharmaceuticals (BCRX) Interest & Investment Income (2010 - 2026)

Biocryst Pharmaceuticals' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• Quarterly Interest & Investment Income fell 25.4% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.9 million (down 27.94% YoY) and the FY2025 annual result came in at $10.7 million, down 27.65% from the prior year.
• Interest & Investment Income was $2.3 million for Q1 2026 at Biocryst Pharmaceuticals, down from $2.9 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $14.9 million in Q4 2023 and bottomed at -$808000.0 in Q3 2022.
• A 5-year average of $3.3 million and a median of $3.0 million in 2025 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income tumbled 80700.0% — and 2023, when it soared 6155.56%.
• Biocryst Pharmaceuticals' Interest & Investment Income stood at $2.7 million in 2022, then soared by 452.37% to $14.9 million in 2023, then sank by 76.1% to $3.6 million in 2024, then declined by 19.05% to $2.9 million in 2025, then dropped by 21.94% to $2.3 million in 2026.
• Business Quant data shows BCRX's Interest & Investment Income at $2.3 million in Q1 2026, $2.9 million in Q4 2025, and $2.2 million in Q3 2025.